{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (OL Phase)"},{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive the same dose of relacorilant as the last dose administered in the OL Phase.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG001","title":"Relacorilant (RW Phase)"},{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive placebo matched to study drug.\n\nPlacebo: Placebo matched to study drug","id":"OG002","title":"Placebo (RW Phase)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population was patients in the Safety Population, which included all enrolled patients who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"OL Phase: Up to 22 weeks; RW Phase: up to 18 weeks after completion of the OL Phase","title":"Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.","type":"PRIMARY","unitOfMeasure":"Participants"}